Photo: Female researcher using a machine in the lab

Ocrelizumab

Ocrelizumab was licensed by the European Medicines Agency in January 2018.

Read more about this licence

In March 2017 it was approved by the US Food and Drug Administration (FDA) as a treatment for both relapsing and primary progressive MS.

Earlier this year in June 2018 NICE approved it for treating relapsing MS. In September 2018, NICE rejected the use of ocrelizumab for primary progressive MS. We're campaigning to change that.

21,000 of you signed a petition to make ocrelizumab available for people with progressive MS. Now we need you to tweet your MP to attend our event in Westminster.

Tweet your MP to show up for ocrelizumab

Not on Twitter? Email your MP to show up for ocrelizumab

Ocrelizumab is an intravenous infusion treatment that has been developed by Roche.

Current phase of trial: Licensed

Type of MS: primary progressive and relapsing MS

Find out more about ocrelizumab

Speak up for ocrelizumab for progressive MS

Ocrelizumab is the first licensed treatment for people with primary progressive MS. We're campaigning for it to be available to them on the NHS.

Tweet your MP to show up for ocrelizumab

Not on Twitter? Email your MP to show up for ocrelizumab